arthritis & osteoporosis care pLLC

41 chenango drive
jericho, new york 11753

NYS Entity Status
ACTIVE

NYS Filing Date
SEPTEMBER 13, 2013

NYS DOS ID#
4458731

County
QUEENS

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC PROFESSIONAL SERVICE LIMITED LIABILITY COMPANY

Name History
2013 - ARTHRITIS & OSTEOPOROSIS CARE PLLC









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Chris Jericho Has His Own Cruise Now, And You Can Sail Away With Him
    By Scott Heisel - Wednesday Sep 20, 2017

    Are you ready to bodyslam the high seas with Chris Jericho, Mick Foley, DDP and more? Get details now.

    Source: Uproxx
  • They Were Shorter and at Risk for Arthritis, but They Survived an Ice Age
    By ANERI PATTANI - Thursday Jul 6, 2017

    A genetic mutation that knocks a centimeter off height and increases the risk for arthritis may have helped early humans in Europe and Asia to survive, a new study shows.

    Source: NYT > Home Page
  • Chris Jericho trades F-bombs in fight with wrestling fan
    By Chris Perez - Monday Jul 31, 2017

    WWE superstar Chris Jericho was caught on camera trading verbal jabs and F-bombs with a wrestling fan in New York City. The Fozzy frontman had been standing outside Irving Plaza on Friday night — after appearing at a tribute show for his late friend and fellow musician David Z — when he got into the...

    Source: New York Post: Entertainment
  • MMA fighter submits opponent with classic WWE move
    By The Sun - Monday Oct 2, 2017

    WWE superstar Chris Jericho has had his celebrated finisher copied by a victorious MMA star. Jericho’s version of a Boston Crab — “The Walls of Jericho” — was borrowed by Jonno Mears for his win over Aaron Jones at the Full Contact Contender 19 show in Bolton, England. The middleweight won his second pro fight...

    Source: New York Post: Sports
  • Bio Roundup: Obamacare Persists, FDA Approves, Vertex Wows & More
    By Alex Lash - Friday Jul 21, 2017

    The attempt to repeal and replace the Affordable Care Act took a major hit this week from Senate GOP holdouts who said the Better Care Reconciliation Act either tore down Medicaid too much or left too much of the ACA in place. A straight-up repeal, floated by Senate majority leader Mitch McConnell, was also shot […]

    Source: Xconomy New York
  • biosimilar drugs can be a hard sell
    By Jared S. Hopkins - Tuesday Aug 15, 2017

    Part of the problem: a web of relationships between drug companies and insurers that shields incumbent drugs and often sidelines upstarts until the market becomes crowded.Pfizer said this month that Inflectra, its version of the blockbuster Johnson & Johnson rheumatoid arthritis drug Remicade, brought in $94 million in the second quarter.J&J spokeswoman Caroline Pavis said in a statement that Remicade is sold in a highly competitive market and that health plans decide on coverage.Doctors and patients tend to be loyal to innovative drugs that have worked well, payers are cautious in adopting alternatives, and Biosimilars can’t be swapped at the pharmacy because they aren’t identical to the drugs they are designed to replace.Remicade, known as infliximab and approved in the U.S. in 1998 for treating the digestive disorder Crohn’s disease, was cleared for rheumatoid arthritis a year later.J&J has exclusive contracts in nearly half its market, according to analyst Ronny Gal of Sanford Bernstein & Co., meaning payers agree to cover only Remicade for rheumatoid arthritis.When Sandoz released white-blood-cell booster Zarxio, the first biosimilar approved in the U.S., two years ago, it cost 15 percent less than Amgen’s Neupogen.[...] Neupogen has gradually lost its dominance, with sales sliding from $1.4 billion in 2013 to $765 million last year.[...] another similar drug, Granix by Teva Pharmaceutical, has been cleared, and Express Scripts last week became the second pharmacy-benefit manager to exclude Neupogen from its list of covered medicines.[...] Kay’s hospital found Inflectra cost $25 more than Remicade a vial, a discrepancy he attributes to pricing negotiations involving the supply chain.Makers of name-brand drugs once opposed biosimilars, citing safety among other concerns, but now say they have the manufacturing muscle and experience to produce and distribute the drugs.“For 20 years, until maybe this year, the brand industry’s position was, ‘Don’t take a biosimilar, it’s scary, it’s dangerous,’” said Bruce Leicher, senior vice president and general counsel at Momenta Pharmaceuticals, which sells generics and is developing Biosimilars.

    Source: SFGATE.com: Business and Technology News